2023
Trends in new and persistent opioid use in older adults with and without cancer
Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.Peer-Reviewed Original ResearchAdditional opioid useNew opioid useOpioid useNon-metastatic cancerPersistent opioid useRetrospective cohort studySolid tumor malignanciesClinical strataEligible patientsNaïve patientsOpioid prescribingMetastatic patientsSurgery patientsCohort studySEER-MedicareMetastatic cancerPatientsTumor malignancyCancerOlder adultsSurgeryRandom sampleAdditional useChemotherapyPrescribing
2019
P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample
Jairam V, Lee V, Park H, Thomas C, Melnick E, Gross C, Presley C, Adelson K, Yu J. P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e51-e52. DOI: 10.1016/s0360-3016(19)30528-0.Peer-Reviewed Original Research
2018
Treatment effect of neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy on breast cancer outcomes.
Pariser A, Mougalian S, Sedghi T, Gross C, Killelea B. Treatment effect of neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy on breast cancer outcomes. Journal Of Clinical Oncology 2018, 36: e12630-e12630. DOI: 10.1200/jco.2018.36.15_suppl.e12630.Peer-Reviewed Original Research
2017
Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy.
Li D, Sun C, Levi A, Klepin H, Elias R, Mohile S, Tew W, Lim D, Chung V, Chao J, Owusu C, Muss H, Lichtman S, Gross C, Chapman A, Gajra A, Cohen H, Katheria V, Hurria A. Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy. Journal Of Clinical Oncology 2017, 35: e21523-e21523. DOI: 10.1200/jco.2017.35.15_suppl.e21523.Peer-Reviewed Original ResearchGI cancersRisk factorsCardiac comorbiditiesOlder adultsGeriatric assessmentOdds ratioLow serum albuminStage IV diseaseIncidence of hospitalizationRisk of hospitalizationAdults age 65Days post treatmentChemotherapy typePatient agePatient characteristicsProspective studyFemale sexGastrointestinal cancerChemotherapy treatmentUnivariate analysisLaboratory valuesHospitalizationChemotherapyMultivariate analysisPatients
2012
RISK OF HEART FAILURE OR CARDIOMYOPATHY ASSOCIATED WITH ADJUVANT TRASTUZUMAB OR CHEMOTHERAPY IN OLDER WOMEN WITH BREAST CANCER
Chen J, Long J, Steingart R, Gross C. RISK OF HEART FAILURE OR CARDIOMYOPATHY ASSOCIATED WITH ADJUVANT TRASTUZUMAB OR CHEMOTHERAPY IN OLDER WOMEN WITH BREAST CANCER. Journal Of The American College Of Cardiology 2012, 59: e996. DOI: 10.1016/s0735-1097(12)60997-8.Peer-Reviewed Original Research
2011
Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo).
Klepin H, Gajra A, Hardt M, Tew W, Mohile S, Owusu C, Gross C, Lichtman S, Ramani R, Katheria V, Brown J, Jayani R, Hansen K, Togawa K, Klapper S, Wong F, Hurria A. Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo). Journal Of Clinical Oncology 2011, 29: 9003-9003. DOI: 10.1200/jco.2011.29.15_suppl.9003.Peer-Reviewed Original ResearchPrimary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes.
Gajra A, Hardt M, Tew W, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Ramani R, Brown J, Katheria V, Jayani R, Hansen K, Togawa K, Klapper S, Hurria A. Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes. Journal Of Clinical Oncology 2011, 29: 9037-9037. DOI: 10.1200/jco.2011.29.15_suppl.9037.Peer-Reviewed Original Research